Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA)

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.7, Iss.10, 2011-10, pp. : 1315-1326

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs

By Wang L.-C. Ching Lai-Ming Paxton James Kestell Philip Sutherland Rachel Zhuang Li Baguley Bruce

Investigational New Drugs, Vol. 27, Iss. 3, 2009-06 ,pp. : 280-284

Springer Publishing Company

Access to resources Recommend Favorite

An improved synthesis of 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

By Atwell G.J. Yang S. Denny W.A.

European Journal of Medicinal Chemistry, Vol. 37, Iss. 10, 2002-10 ,pp. : 825-828

Elsevier

Access to resources Recommend Favorite

Temporal aspects of the action of ASA404 (vadimezan; DMXAA)

By Baguley Bruce C Siemann Dietmar W

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 11, 2010-11 ,pp. : 1413-1425

Informa Healthcare

Access to resources Recommend Favorite

Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

By Zhao Liangli Marshall Elaine Kelland Lloyd Baguley Bruce

Investigational New Drugs, Vol. 25, Iss. 3, 2007-06 ,pp. : 271-276

Springer Publishing Company

Access to resources Recommend Favorite

The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities

By Head Michelle Jameson Michael B

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 2, 2010-02 ,pp. : 295-304

Informa Healthcare

Access to resources Recommend Favorite